Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
Nektar Therapeutics (NASDAQ:NKTR) experienced a boost in analyst sentiment on December 16, 2025, following strong topline results from the 36-week induction period of the Phase 2b REZOLVE-AA study. The trial narrowly missed its primary endpoint; however, Oppenheimer highlighted that omitting four patients with eligibility violations yielded nominal statistical significance. Seeing compelling activity for rezpegaldesleukin, the firm raised the probability of success for the indication to 50%. Accordingly, the bank increased its price target on Nektar Therapeutics (NASDAQ:NKTR) from $98 to $115, while maintaining an “Outperform” rating, according to The Fly . Meanwhile, H.C. Wainwright also expressed optimism the same day, raising its price target from $120 to $135 on Nektar Therapeutics (NASDAQ:NKTR) with a “Buy” rating. Citing the topline results as encouraging, the firm raised its probability of rezpegaldesleukin launch for alopecia areata to 25%. H.C. Wainwright projects risk-adjus
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions [Seeking Alpha]Seeking Alpha
- Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $100.00 to $118.00. They now have a "buy" rating on the stock.MarketBeat
- Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- iShares MSCI EAFE Growth ETF declares semi-annual distribution of $1.8057 [Seeking Alpha]Seeking Alpha
NKTR
Earnings
- 11/6/25 - Beat
NKTR
Sec Filings
- 12/16/25 - Form 8-K
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- NKTR's page on the SEC website